Antiretroviral penetration into the CNS and incidence of AIDS-defining neurologic conditions

Neurology

Volumn 83, Issue 2, 2014, Pages 134-141

  Caniglia, Ellen C ^a   Cain, Lauren E ^a   Justice, Amy ^b,c   Tate, Janet ^b   Logan, Roger ^a   Sabin, Caroline ^d   Winston, Alan ^e   Van Sighem, Ard ^f   Miro, Jose M ^g   Podzamczer, Daniel ^h   Olson, Ashley ⁱ   Arribas, José Ramón ^j   Moreno, Santiago ^k   Meyer, Laurence ^l   Del Romero, Jorge ^m   Dabis, François ⁿ   Bucher, Heiner C ^o   Wandeler, Gilles ^p   Vourli, Georgia ^q   Skoutelis, Athanasios ^r   Lanoy, Emilie ^s   Gasnault, Jacques ^t   Costagliola, Dominique ^u   Hernán, Miguel A ^a   more..

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c YALE UNIVERSITY   (United States)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

^f STICHTING HIV MONITORING   (Netherlands)

^g HOSPITAL CLÍNIC   (Spain)

^h HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

ⁱ MRC CLINICAL TRIALS UNIT   (United Kingdom)

^j HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^k HOSPITAL RAMÓN Y CAJAL   (Spain)

^l CENTRE FOR RESEARCH IN EPIDEMIOLOGY AND POPULATION HEALTH   (France)

^m CENTRO SANITARIO SANDOVAL   (Spain)

ⁿ UNIVERSITÉ DE BORDEAUX   (France)

^o UNIVERSITY HOSPITAL BASEL   (Switzerland)

^p UNIVERSITY OF BERN   (Switzerland)

^q UNIVERSITY OF ATHENS   (Greece)

^r IASO GENERAL HOSPITAL   (Greece)

^s INSTITUT GUSTAVE ROUSSY   (France)

^t BICÊTRE HOSPITAL   (France)

^u INSERM   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; EFAVIRENZ; EMTRICITABINE; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; RITONAVIR; TENOFOVIR; ZIDOVUDINE;

ADULT; ARTICLE; CLINICAL EFFECTIVENESS; CNS PENETRATION EFFECTIVENESS SCORE; COHORT ANALYSIS; CRYPTOCOCCAL MENINGITIS; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HAZARD RATIO; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED DEMENTIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; INCIDENCE; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; TOXOPLASMOSIS; AIDS DEMENTIA COMPLEX; CASE MANAGEMENT; CD4 LYMPHOCYTE COUNT; CENTRAL NERVOUS SYSTEM; COMPLICATION; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; METABOLISM; MIDDLE AGED; PROCEDURES; PROSPECTIVE STUDY; STATISTICAL MODEL; YOUNG ADULT;

ADULT; AIDS DEMENTIA COMPLEX; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CASE MANAGEMENT; CD4 LYMPHOCYTE COUNT; CENTRAL NERVOUS SYSTEM; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HIV-1; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84904022110     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000000564     Document Type: Article

References (36)

1. Wright E. Neurological complications of long-term treated HIV disease: what's on your mind? Presented at the 19th Conference on Retroviruses and Opportunistic Infections (CROI); Seattle; 2012.
2. Sacktor N. The epidemiology of human immunodeficiency virus-associated neurological disease in the era of highly active antiretroviral therapy. J Neurovirol 2002;8 (suppl 2): 115-121.
3. Heaton R, Clifford D, Frankin DJ, et al. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology 2010;75: 2087-2096.
4. Sacktor N, Lyles R, Skolasky R, et al. HIV-associated neurologic disease incidence changes: Multicenter AIDS Cohort Study, 1990-1998. Neurology 2001;56: 257-260.
5. d'Arminio Monforte A, Cinque P, Mocroft A, et al. Changing incidence of central nervous system diseases in the EuroSIDA cohort. Ann Neurol 2004;55: 320-328.
6. Engsig F, Hansen A, Omland L, et al. Incidence, clinical presentation, and outcome of progressive multifocal leukoencephalopathy in HIV-infected patients during the highly active antiretroviral therapy era: a nationwide cohort study. J Infect Dis 2009;199: 77-83.
7. Khanna N, Elzi L, Mueller N, et al. Incidence and outcome of progressive multifocal leukoencephalopathy over 20 years of the Swiss HIV Cohort Study. Clin Infect Dis 2009;48: 1459-1466.
8. Garvey L, Winston A, Walsh J, et al UK Collaborative HIV Cohort (CHIC) Study Steering Committee. HIVassociated central nervous system diseases in the recent combination antiretroviral therapy era. Eur J Neurol 2011;18: 527-534.
9. Lescure F, Omland L, Engsig F, et al. Incidence and Impact on mortality of severe neurocognitive disorders in persons with and without HIV infection: a Danish nationwide cohort study. Clin Infect Dis 2011;52: 235-243.
10. Robertson K, Su Z, Margolis D, et al. Neurocognitive effects of treatment interruption in stable HIV-positive patients in an observational cohort. Neurology 2010;74: 1260-1266.
11. Mothobi N, Brew B. Neurocognitive dysfunction in the highly active antiretroviral therapy era. Curr Opin Infect Dis 2012;25: 4-9.
12. Liner KJ, Ro MJ, Robertson K. HIV, antiretroviral therapies, and the brain. Curr HIV/AIDS Rep 2010;7: 85-91.
13. Letendre S, Marquie-Beck J, Capparelli E, et al. Validation of the CNS penetration-effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol 2008;65: 65-70.
14. Letendre S. Background and rationale of the CPE score. Presented at the 2nd International Workshop on HIV & Aging. Baltimore; 2011.
15. Robertson K, Liner J, Meeker R. Antiretroviral neurotoxicity. J Neurovirol 2012;18: 388-399.
16. Letendre S. Central nervous system complications in HIV disease: HIV-associated neurocognitive disorder. Top Antivir Med 2011;19: 137-142.
17. Marra C, Zhao Y, Clifford D, et al. Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance. AIDS 2009;23: 1359-1366.
18. Cusini A, Vernazza P, Yerly S, et al. Higher CNS penetration- effectiveness of long-term combination antiretroviral therapy is associated with better HIV-1 viral suppression in cerebrospinal fluid. J Acquir Immune Defic Syndr 2013;62: 28-35.
19. Cysique L, Vaida F, Letendre S, et al. Dynamics of cognitive change in impaired HIV-positive patients initiating antiretroviral therapy. Neurology 2009;73: 342-348.
20. Tozzi V, Balestra P, Salvatori M, et al. Changes in cognition during antiretroviral therapy: comparison of 2 different ranking systems to measure antiretroviral drug efficacy on HIV-associated neurocognitive disorders. J Acquir Immune Defic Syndr 2009;52: 56-63.
21. Ciccarelli N, Fabbiani M, Di Giambenedetto S, et al. Efavirenz associated with cognitive disorders in otherwise asymptomatic HIV-infected patients. Neurology 2011; 76: 1403-1409.
22. Lanoy E, Guiguet M, Bentata M, et al. Survival after neuro-AIDS: association with antiretroviral CNS penetrationeffectiveness score. Neurology 2011;76: 644-651.
23. Ellis R, Letendre S, Vaida F, et al. A randomized, controlled trial of a central nervous system-targeted ART strategy for HIV-associated neurocognitive disorders. Presented at the 20th Conference on Retroviruses and Opportunistic Infections. Atlanta; 2013.
24. Garvey L, Winston A, Walsh J, et al. Antiretroviral therapy CNS penetration and HIV-1-associated CNS disease. Neurology 2011;76: 693-700.
25. -1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 1992;41: 1-9.
26. Ray M, Logan R, Sterne JA, et al HIV-CAUSAL Collaboration. The effect of combined antiretroviral therapy on overall mortality of HIV-infected individuals. AIDS 2010; 24: 123-137.
27. D'Agostino R, Lee M, Belanger A, Cupples L, Anderson K, Kannel W. Relation of pooled logistic regression to time dependent Cox regression analysis: the Framingham Heart Study. Stat Med 1990;9: 1501-1515.
28. Hernán M, Brumback B, Robins J. Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men. Epidemiology 2000;11: 561-570.
29. Sterne J, Hernan M, Ledergerber B, et al. Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study. Lancet 2005;366: 378-384.
30. Robins J. Marginal structural models. In: 1997 Proceedings of the American Statistical Association, Section on Bayesian Statistical Science, Alexandria, VA. 1998: 1-10.
31. Tate J, Justice A, Hughes M, et al. An internationally generalizable risk index for mortality after one year of antiretroviral therapy. AIDS 2013;27: 563-572.
32. Lau B, Cole S, Gange S. Competing risk regression models for epidemiologic data. Am J Epidemiol 2009;170: 244-256.
33. Ciccarelli N, Fabbiani M, Colafigli M, et al. Revised central nervous system neuropenetration-effectiveness score is associated with cognitive disorders in HIV-infected patients with controlled plasma viraemia. Antivir Ther 2013;18: 153-160.
34. Giunta B, Ehrhart J, Obregon D, et al. Antiretroviral medications disrupt microglial phagocytosis of b-amyloid and increase its production by neurons: implications for HIVassociated neurocognitive disorders. Mol Brain 2011;4: 4-23.
35. Xu J, Ikezu T. The comorbidity of HIV-associated neurocognitive disorders and Alzheimer's disease: a foreseeable medical challenge in post-HAART era. J Neuroimmune Pharmacol 2009;4: 200-212.
36. Achim C, Adame A, Dumaop W, Everall I, Masliah E; Neurobehavioral Research Center. Increased accumulation of intraneuronal amyloid b in HIV-infected patients. J Neuroimmune Pharmacol 2009;4: 190-199.